News
Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...
Plus more pharma news from the Pharmalittle newsletter.
Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
Massachusetts biotechs saw their stock prices rise after news broke that FDA Vinay Prasad is leaving the agency.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results